Back to Results
First PageMeta Content
Medicine / Gastroenterology / Diabetes / Eli Lilly and Company / Clinical research / European Medicines Agency / Anti-diabetic medication / Exenatide / Glucagon-like peptide-1 / Anti-diabetic drugs / Peptide hormones / Endocrine system


Lyxumia - INN, lixisenatide
Add to Reading List

Document Date: 2013-07-21 06:40:43

Open Document

File Size: 1,67 MB

Share Result on Facebook

City

London / Frankfurt am Main / /

Company

Sun / Sanofi-Aventis Deutschland GmbH / /

Country

Germany / United Kingdom / /

/

Facility

Canary Wharf / /

IndustryTerm

above medicinal product / µg solution / chemical and microbiological stability / pharmaceutical and biological aspects / pharmaceutical development / authorised orphan medicinal products / drug product / pharmaceutical use / medicinal product / chemical stability / chemical / authorised orphan medicinal product / degradation products / treatment algorithm / sterile solution / manufacturing process / /

MedicalCondition

insulin resistance / chronic widespread disease / ARAC allergic reaction / diabetes / MI myocardial infarction / diabetes mellitus / MS / /

Organization

Human Use / European Medicines Agency / European Association for the Study of Diabetes / Committee for Medicinal Products for Human Use / European Union / CHMP Committee for Medicinal Products / E-mail info@ema.europa.eu Website www.ema.europa.eu An / American Diabetes Association / /

Person

Karl Fischer / Pieter de Graeff / Agnes Gyurasics / Walter Janssens / /

/

Product

glucagon / Sodium acetate / /

Technology

Pharmacokinetics / treatment algorithm / X-ray / spectroscopy / Pharmacodynamics / /

URL

www.ema.europa.eu / /

SocialTag